Systemic immunomodulating therapies for epidermal necrolysis (Stevens‐Johnson syndrome/toxic epidermal necrolysis): A systematic review and meta‐analysis
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2026-01 · 24 (1) · 34-42
DOI: 10.1111/ddg.15804 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 04.09.2025. Verfasst von Ruben Heuer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Evidence-based Medicine (dEBM), Department of Dermatology, Venereology and Allergy, Charité - University Medicine Berlin, Corporate Membe…. Hauptthemen laut MEDLINE: Stevens-Johnson Syndrome, Immunomodulating Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives Epidermal necrolysis is a rare but severe cutaneous reaction with high mortality. Limited evidence exists regarding the efficacy of systemic immunomodulatory therapies (SITs). Our systematic review aimed to compare SITs with supportive care or one another. Patients and Methods Randomized controlled trials and controlled observational studies (≥ 5 patients of all ages per arm) using the international consensus classification for EN (Bastuji‐Garin, 1993) with no significant baseline differences were included. We searched MEDLINE, Embase, and Cochrane CENTRAL (January 1, 1993–January 22, 2024). Two reviewers independently extracted study and outcome data. A random‐effects meta‐analysis was performed.
Results
The main outcome was mortality. Secondary outcomes included hospital stay duration, time to complete reepithelialization, complications, and sequelae. 43 studies with 58 treatment comparisons were analyzed. Cyclosporine was superior to IVIG regarding mortality (RR 0.18, 95% CI 0.05–0.58), and corticosteroids plus IVIG reduced serious complications compared to corticosteroids alone (sepsis, RR 0.77, 95% CI 0.31–0.77). Compared to supportive care, only etanercept showed a significant mortality benefit (RR 0.32, 95% CI 0.11–0.93; GRADE: imprecision/unclear clinical importance).
Conclusions
There is no clear evidence of the superiority of SITs over supportive care, which remains the primary treatment for EN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Evidence-based Medicine (dEBM), Department of Dermatology, Venereology and Allergy, Charité - University Medicine Berlin, Corporate Member of Free University of Berlin, Humboldt University of Berlin, and Ber…
- Dokumentationszentrum schwerer Hautreaktionen (dZh), Department of Dermatology, Medical Center - University of Freiburg, Freiburg, Germany.
ORCID-Profile: Ruben Heuer, Alexander Nast
Zitieren
APA
Heuer, R., Paulmann, M., Mockenhaupt, M., & Nast, A. (2026). Systemic immunomodulating therapies for epidermal necrolysis (Stevens‐Johnson syndrome/toxic epidermal necrolysis): A systematic review and meta‐analysis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 24(1), 34-42. https://doi.org/10.1111/ddg.15804
Vancouver
Heuer R, Paulmann M, Mockenhaupt M, Nast A. Systemic immunomodulating therapies for epidermal necrolysis (Stevens‐Johnson syndrome/toxic epidermal necrolysis): A systematic review and meta‐analysis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026;24(1):34-42. doi:10.1111/ddg.15804
BibTeX
@article{Heuer2026,
author = {Heuer, Ruben and Paulmann, Maren and Mockenhaupt, Maja and Nast, Alexander},
title = {Systemic immunomodulating therapies for epidermal necrolysis (Stevens‐Johnson syndrome/toxic epidermal necrolysis): A systematic review and meta‐analysis},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2026},
volume = {24},
number = {1},
pages = {34--42},
doi = {10.1111/ddg.15804}
}
EUVIMED